Navigation Links
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of Phase III data, including efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptor antagonist and sigma-1 agonist. The data were accepted as 'late-breakers' and presented in two posters at the Second International Congress on Neuropathic Pain (ICNP) in Berlin.

DPN pain is a common complication of diabetes that has significant impact on outcomes of concern to patients including sleep, activity and quality of life. In a multi-center, 3-month, double-blind Phase III trial, active treatment with Zenvia 45/30 mg dosed twice daily (DM/Q 45) and 30/30 mg DM/Q dosed twice daily (DM/Q 30) over a three month period, was compared to placebo. AVANIR previously announced in April 2007 that both doses of Zenvia had met the primary endpoint of statistically significant improvements versus placebo as recorded in daily patient diary entries using the Pain Rating Scale, as defined in the Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). In addition the DM/Q 45 met statistical significance for 4 out of 5 secondary endpoints reported.

Highlights of new Zenvia data presented at ICNP:

-- DM/Q 45 achieved 53%, 59% and 59% improvement versus baseline, DM/Q 30 achieved 43%, 48% and 48% improvement and placebo achieved 27%, 34% and 39% improvement at days 30, 60 and 90, respectively in the Pain Rating Scale.

-- 28% of patients in the DM/Q 45 arm and 27% in the DM/Q 30 arm obtained "a lot" of or "complete" pain relief at three months versus 17% in the placebo group (p=0.0008 and p=0.0017 respectively)

-- Active treatment with both Zenvia doses significantly reduced pain interference with
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/28/2015)... 2015  PD-Rx Pharmaceuticals, Inc., a publicly held ... partnered with Dobson Technologies, a fully-integrated outsourced IT ... product. PD-Rx is an Application Service ... States.  Using Dobson Technologies, IaaS solution will allow ... ensure regulatory compliance, and reduce operating expenses.  "The ...
(Date:7/28/2015)... July 28, 2015   Vincari , known for ... has just hired John O,Neil as their ... has over 30 years of diverse and progressive experience ... executive healthcare experience coupled with Vincari,s CMO, Dr. ... Vincari to address the challenges both hospitals and surgeons ...
(Date:7/28/2015)... , July 28, 2015  Leaf Healthcare releases ... pressure ulcers place on the healthcare system . ... threat to modern quality healthcare. Research by the ... for Healthcare Research and Quality shows that pressure ... $11 billion a year. The condition is both ...
Breaking Medicine Technology:PD-Rx Partners With Dobson Technologies 2John O'Neil Joins Vincari as Executive Vice President of Strategy and Business Development 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 3
(Date:7/28/2015)... ... ... Santa Rosa’s The Press Democrat announced its annual report of the very best facilities in ... Furnas took the top spot as the Best Cosmetic Surgeons in Sonoma County . ... be bestowed such a prestigious title. , The Press Democrat was Santa Rosa’s ...
(Date:7/28/2015)... ... ... Her, a unique women’s wellness and lifestyle event designed to inspire and empower women ... level, announced today an influential line-up of inspiring speakers, including Mallika Chopra, founder of ... County based non-profit that works locally and globally to help girls become leaders in ...
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... and Found, a breakthrough technological invention. It is a wearable personal tracking ... electronic industry reached a record high of $211.3 billion in 2014," says Scott ...
(Date:7/28/2015)... ... July 28, 2015 , ... By 2016, the number of ... to engage with customers on a highly personal basis, increasing customer loyalty. However, capitalizing ... big growth opportunities or lose customers to more nimble competitors. , The Open Mobile ...
(Date:7/28/2015)... ... 28, 2015 , ... Autism is the fastest growing serious ... with the disorder. For these families, identifying and paying for the help they ... That’s where Talk About Curing Autism (TACA), a national non-profit organization dedicated to ...
Breaking Medicine News(10 mins):Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2
... have developed an effective technique that uses gene therapy on ... culture, which could eventually serve as a treatment for this ... published in Blood , the Journal of ... a type of white blood cell of the immune system, ...
... common in Germany compared with the rest of Europe. Extensive ... in 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue ... Arztebl Int 2011; 108[15]; 249-54). A woman,s folic acid ... does not develop the neural tube defect commonly known as ...
... The largest study of its type has found that ... drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver ... in the April 27, 2011 issue of Journal of ... in patients with a severe type of fatty liver disease, ...
... oncologist practiced were two factors that strongly influenced the choice ... to an article published April 29 online in the ... IMRT and the cost of radiation therapy increased sharply over ... delivery technique that modulates the radiation beams to conform to ...
... with the Japanese Bone and Mineral Research Society, invite ... bone research to attend the year,s most important bone ... Gold Coast in Queensland, Australia, the congress will present ... on the latest advances in the clinical management of ...
... , THURSDAY, April 28 (HealthDay News) -- ... may already know: the illness can greatly diminish quality of ... took part in the national Behavioral Risk Factor Surveillance ... health was reported by 27 percent of respondents with arthritis ...
Cached Medicine News:Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 2Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 3Health News:JAMA study reports on fatty liver disease in children and teens 2Health News:Use of costly breast cancer therapy strongly influenced by reimbursement policy 2Health News:Preliminary program announced for 2nd Asia-Pacific Osteoporosis & Bone Meeting 2Health News:Study Highlights Arthritis' Toll on Quality of Life 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: